It hit $13.40 on August 3rd and closed at $11.625 the same day and CTSO reported the amendment on August 3rd. EXPLANATORY NOTE
CytoSorbents Corporation has prepared this Amendment No. 1 (this “Amendment No. 1”) to its Registration Statement on Form S-3, filed with the Securities and Exchange Commission (the “SEC”) on July 26, 2018 (the “Registration Statement”), solely to incorporate by reference its Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the SEC on August 2, 2018. No other change is made to the prospectus constituting Part I of the Registration Statement or Part II of the Registration Statement.
This registration statement contains two prospectuses:
· a base prospectus, which covers the offering, issuance and sale by us of up to $150,000,000 in the aggregate of the securities identified above from time to time in one or more offerings; and
· a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $25,000,000 of our common stock that may be issued and sold under that certain Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., dated November 4, 2015 (as amended by that certain Amendment No. 1 to Sales Agreement, dated as of July 26, 2018, the “Sales Agreement”).